-
XOMA - XOMA Corp
XOMA Corp (XOMA) a bio-tech company has had a hot chart over the past few months. Primarily driven by a large hedge fund buyer that is known to take interests in bio-techs with great upside potential. Not that I use this information to trade, its just good to know. However, I will trade the chart, and currently it's showing it could be setting up for the next leg higher.
-
Head And Shoulders: Can They Save It From Triggering
The U.S. markets are trading flat on the day after an ugly overnight session in the S&P futures. The SPDR S&P 500 ETF (NYSEARCA:SPY) is trading at $136.91, -0.05 (-0.04%) after the S&P futures were down as much as 20 points overnight. This surge back was helped by the weakening Dollar and the strengthening Euro off their overnight highs and lows.
Yesterday, the people France and Greece sent a clear message to their leaders. The austerity measures being implemented are not favored and those who pushed them through were voted out of office. This brings more uncertainty into the European picture in relation to the EU.
The rebound in stocks were headed by the banks like JPMorgan Chase & Co. (NYSE:JPM) and Goldman Sachs Group, Inc. (NYSE:GS). In addition, there are key technical patterns on the charts that are showing a break down is extremely near but has not triggered. Note the head and shoulder pattern on the chart below. It has not triggered yet but may, depending on where the market closes today.
Gareth Soloway
-
Antichartjunk.com's Week 19 Update
Buy or Sell: Sell
Long Into Week 19 ? CSTR, LULU, RAX
Add to watchlist as initial or secondary buys, but do not buy until market shows buy signals:
ALXN ? 95.11 to 99.87
AMT ? 64.65 to 67.88
AZO ? 386.11 to 405.42
CHS ? 15.89 to 16.68
DG ? 47.69 to 50.08
FUL ? 31.72 to 33.31
GCO ? 75.65 to 79.
KORS ? 50.79 to 53.33
TCBI ? 35.71 to 37.50
TNGO ? 20 to 21
Add to watchlist as secondary buys only, but do not buy until market shows buy signals:
CMG ? bounce from 50-day
CSTR ? 63.89
FOSL ? bounce from 50-day
MA ? bounce from 50-day
PCLN ? bounce from 50-day
RAX ? bounce from 50-day
SHFL ? bounce from 50-day
SWI ? 47.76
-
CHK - trading around a 2 year support
CHK is trading at the support, worth watching.
-
Penny Stock Watchlist 5/7
Decent Friday, always like to hear others in chat posting their gains. A few banked on TTDZ (scam company, I know) but buyers were coming in on those fake-ass financials posted Friday, so I alerted it about .0018 and said it may run over .002, sure enough, peaked just under .004, and yes I recommended taking profits in the high .003's if anyone had taken the idea. Seemed to a few sub-penny runners on Friday (DGRI SDIR ISIM USEI, etc). Some days when the market is slow, the low priced pos stocks come to life as everyone is just looking for something to buy. Here's the list for Monday:
ABAT AFFX AMBS AUTH CCAJ DGRI GNBA EQU HLCS IFON ISIM KGJI LUVU MITK PPP PRTS PTAM SDIR SNRY STRI TTDZ USEI VKNG VRNG
Over $5: YPF CALX DGI DOLE VHC COT ENOC RENN
-
Weekly Market Review 201218
Market disappointed with the weak jobs data, even though the unemployment rate took a small step back from 8.2% to 8.1% in April, nonfarm payrolls added the least jobs ( 115k vs. 163k est.) since November 2011. Stocks gave up almost the entire gains that were generated in late April. On the other hand, fixed income products buoy from this pessimistic employment print, the 10yr Treasury yield is currently trading at 1.83%, which is just 10bps away from its all time low. Looking forward next week, investors will continue to monitor with the initial jobless claims for any possible signal of economy slowdown.
Technical Highlights:
? Stocks took a big step down after disappointed data that led to a clear lower high technical formation for a downtrend.
? Although the moving averages are still pointing upward, equity benchmark internals showed weakness as percentage of stocks above 200 day moving average failed below its support since January.
? RSMCs rallied strong across three defensive benchmarks, which is signaling for a major trend change.
? Stocks continued their way down, defensive is the key trade as historical return points for a positive return potential.
? The yields on the intermediate term bonds appeared negative correlation with the shorter maturity bonds, which may be signaling for short-term pullback.
read more at...
-
VECO (Coverage Initiated)
Coverage Initiated:
VECO (Long/$32.8 Stop) - The chart pattern is showing very early signs of a developing ascending channel. The stock gapped higher May 1st after an earnings release and has continued to show relative strength. This four bar pattern clearly shows the bulls are in control and we will be looking for a long entry at a break of $35.81 which was Friday's high.
-
FFN Stock to watch!
With the Facebook right around the corner this one could pop this stock looks as if it wants to go up atleast 20-30 more cents, could be some good money if you get in now!
-
Care Fusion Corporation (CFN)
Nice breakout on heavy volume, positive macd. look for a quick run to $28.25 then on to $30
-
Xenoport, Inc. (XNPT) - Stock With Huge Potential In June
Stock is building a base here with a "W" chart pattern which means it will go back up. As I mentioned on Twitter, I bought this stock waiting for something BIG in June.
From seeking alpha :
XenoPort is a biopharmaceutical company focused on developing and commercializing a portfolio of internally discovered product candidates for the potential treatment of neurological disorders. Horizant (gabapentin enacarbil) Extended-Release Tablets is XenoPort's first FDA-approved product. Regnite (gabapentin enacarbil) is approved in Japan for the treatment of moderate to severe primary restless legs syndrome. XenoPort's pipeline of product candidates includes potential treatments for patients with postherpetic neuralgia, spasticity, and Parkinson's disease.
The FDA has accepted for review the supplemental new drug application (SNDA) filed by GlaxoSmithKline (GSK) requesting approval of Horizant (gabapentin enacarbil) Extended-Release Tablets for the treatment of postherpetic neuralgia in adults. The FDA has set a PDUFA date of June 9, 2012, as a goal for the completion of their review of the SNDA.
On April 4, 2012, XenoPort announced that it was awarded U.S. Patent 8,148,414 for "Prodrugs of Methyl Hydrogen Fumarate, Pharmaceutical Compositions Thereof, and Methods of Use." The term of the patent extends until 2029, subject to potential Hatch-Waxman patent term extensions.
XenoPort has a market cap of $162.82 million and it is currently trading around $4.57 with a 52-week range of $3.46 to $8.44.